Brief: Pacira Biosciences Q3 Adjusted Net Income USD 38.2 Million Vs. IBES Estimate USD 34.9 Million
06/11/2024 21:00
Nov 06 (Reuters) - Pacira Biosciences Q3 revenue USD 168.6 million vs. IBES estimate USD 169.7 million. * Q3 cash & investments USD 453.8 million * Q3 adjusted EBITDA USD 54.7 million vs. IBES estimate USD 51.8 million * Q3 net income USD -143.5 million
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees